# Improving Post-Prandial Blood Glucose Control With Afrezza During Closed-Loop Therapy

> **NCT03234491** · PHASE1 · COMPLETED · sponsor: **Yale University** · enrollment: 15 (actual)

## Conditions studied

- Post-Prandial Hyperglycemia
- Post-Prandial Hypoglycemia

## Interventions

- **DEVICE:** DiAS
- **DRUG:** Afrezza low dose
- **DRUG:** Afrezza high dose

## Key facts

- **NCT ID:** NCT03234491
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-22
- **Primary completion:** 2019-07-22
- **Final completion:** 2019-07-22
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2022-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03234491

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03234491, "Improving Post-Prandial Blood Glucose Control With Afrezza During Closed-Loop Therapy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03234491. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*